ID   EPN2_RAT                Reviewed;         583 AA.
AC   Q9Z1Z3;
DT   16-JAN-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1999, sequence version 1.
DT   24-JUL-2024, entry version 135.
DE   RecName: Full=Epsin-2;
DE   AltName: Full=EPS-15-interacting protein 2;
GN   Name=Epn2;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, INTERACTION WITH EPS15, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Brain;
RX   PubMed=10567358; DOI=10.1074/jbc.274.48.33959;
RA   Rosenthal J.A., Chen H., Slepnev V.I., Pellegrini L., Salcini A.E.,
RA   Di Fiore P.P., De Camilli P.;
RT   "The epsins define a family of proteins that interact with components of
RT   the clathrin coat and contain a new protein module.";
RL   J. Biol. Chem. 274:33959-33965(1999).
RN   [2]
RP   UBIQUITINATION.
RX   PubMed=11919637; DOI=10.1038/416451a;
RA   Polo S., Sigismund S., Faretta M., Guidi M., Capua M.R., Bossi G., Chen H.,
RA   De Camilli P., Di Fiore P.P.;
RT   "A single motif responsible for ubiquitin recognition and
RT   monoubiquitination in endocytic proteins.";
RL   Nature 416:451-455(2002).
RN   [3]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-192; SER-195; SER-431 AND
RP   THR-453, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
CC   -!- FUNCTION: Plays a role in the formation of clathrin-coated
CC       invaginations and endocytosis. {ECO:0000269|PubMed:10567358}.
CC   -!- SUBUNIT: Binds AP-2 and clathrin (By similarity). Interacts with ITSN1
CC       (By similarity). Interacts with UBQLN2 (By similarity). Binds EPS15.
CC       {ECO:0000250|UniProtKB:O95208, ECO:0000250|UniProtKB:Q8CHU3,
CC       ECO:0000269|PubMed:10567358}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Note=In punctate
CC       structures throughout the cell and particularly concentrated in the
CC       region of the Golgi complex. {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Highly expressed in brain. Detected at lower levels
CC       in lung, liver, muscle and testis. {ECO:0000269|PubMed:10567358}.
CC   -!- DOMAIN: The NPF repeat domain is involved in EPS15 binding.
CC   -!- DOMAIN: The DPW repeat domain is involved in AP-2 and clathrin binding.
CC   -!- PTM: Ubiquitinated. {ECO:0000269|PubMed:11919637}.
CC   -!- SIMILARITY: Belongs to the epsin family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF096269; AAC79495.1; -; mRNA.
DR   AlphaFoldDB; Q9Z1Z3; -.
DR   SMR; Q9Z1Z3; -.
DR   BioGRID; 248836; 2.
DR   STRING; 10116.ENSRNOP00000074461; -.
DR   iPTMnet; Q9Z1Z3; -.
DR   jPOST; Q9Z1Z3; -.
DR   PaxDb; 10116-ENSRNOP00000039386; -.
DR   UCSC; RGD:619773; rat.
DR   AGR; RGD:619773; -.
DR   RGD; 619773; Epn2.
DR   InParanoid; Q9Z1Z3; -.
DR   Reactome; R-RNO-8856825; Cargo recognition for clathrin-mediated endocytosis.
DR   Reactome; R-RNO-8856828; Clathrin-mediated endocytosis.
DR   PRO; PR:Q9Z1Z3; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0030128; C:clathrin coat of endocytic vesicle; IDA:RGD.
DR   GO; GO:0030125; C:clathrin vesicle coat; IBA:GO_Central.
DR   GO; GO:0005768; C:endosome; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0098843; C:postsynaptic endocytic zone; IDA:SynGO.
DR   GO; GO:0030276; F:clathrin binding; IBA:GO_Central.
DR   GO; GO:0005543; F:phospholipid binding; IBA:GO_Central.
DR   GO; GO:0048568; P:embryonic organ development; ISO:RGD.
DR   GO; GO:0006897; P:endocytosis; IBA:GO_Central.
DR   GO; GO:0001701; P:in utero embryonic development; ISO:RGD.
DR   GO; GO:1903671; P:negative regulation of sprouting angiogenesis; ISO:RGD.
DR   GO; GO:0030948; P:negative regulation of vascular endothelial growth factor receptor signaling pathway; ISO:RGD.
DR   GO; GO:0007219; P:Notch signaling pathway; ISO:RGD.
DR   GO; GO:0045747; P:positive regulation of Notch signaling pathway; ISO:RGD.
DR   GO; GO:0030100; P:regulation of endocytosis; IDA:RGD.
DR   CDD; cd16990; ENTH_Epsin; 1.
DR   Gene3D; 1.25.40.90; -; 1.
DR   InterPro; IPR013809; ENTH.
DR   InterPro; IPR008942; ENTH_VHS.
DR   InterPro; IPR003903; UIM_dom.
DR   PANTHER; PTHR12276:SF50; EPSIN-2; 1.
DR   PANTHER; PTHR12276; EPSIN/ENT-RELATED; 1.
DR   Pfam; PF01417; ENTH; 1.
DR   SMART; SM00273; ENTH; 1.
DR   SMART; SM00726; UIM; 2.
DR   SUPFAM; SSF48464; ENTH/VHS domain; 1.
DR   PROSITE; PS50942; ENTH; 1.
DR   PROSITE; PS50330; UIM; 2.
PE   1: Evidence at protein level;
KW   Cytoplasm; Endocytosis; Lipid-binding; Methylation; Phosphoprotein;
KW   Reference proteome; Repeat; Ubl conjugation.
FT   CHAIN           1..583
FT                   /note="Epsin-2"
FT                   /id="PRO_0000074518"
FT   DOMAIN          12..144
FT                   /note="ENTH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00243"
FT   DOMAIN          218..237
FT                   /note="UIM 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00213"
FT   DOMAIN          243..262
FT                   /note="UIM 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00213"
FT   REPEAT          301..303
FT                   /note="1"
FT   REPEAT          313..315
FT                   /note="2"
FT   REPEAT          326..328
FT                   /note="3"
FT   REPEAT          340..342
FT                   /note="4"
FT   REPEAT          358..360
FT                   /note="5"
FT   REPEAT          375..377
FT                   /note="6"
FT   REPEAT          482..484
FT                   /note="1"
FT   REPEAT          496..498
FT                   /note="2"
FT   REPEAT          579..581
FT                   /note="3"
FT   REGION          165..217
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          293..384
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          301..377
FT                   /note="6 X 3 AA repeats of [DE]-P-W"
FT   REGION          411..457
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          482..581
FT                   /note="3 X 3 AA repeats of N-P-F"
FT   COMPBIAS        165..185
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        194..217
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        297..319
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        344..370
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        422..455
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         8
FT                   /ligand="a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-
FT                   inositol-4,5-bisphosphate)"
FT                   /ligand_id="ChEBI:CHEBI:58456"
FT                   /evidence="ECO:0000250"
FT   BINDING         11
FT                   /ligand="a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-
FT                   inositol-4,5-bisphosphate)"
FT                   /ligand_id="ChEBI:CHEBI:58456"
FT                   /evidence="ECO:0000250"
FT   BINDING         25
FT                   /ligand="a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-
FT                   inositol-4,5-bisphosphate)"
FT                   /ligand_id="ChEBI:CHEBI:58456"
FT                   /evidence="ECO:0000250"
FT   BINDING         30
FT                   /ligand="a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-
FT                   inositol-4,5-bisphosphate)"
FT                   /ligand_id="ChEBI:CHEBI:58456"
FT                   /evidence="ECO:0000250"
FT   BINDING         63
FT                   /ligand="a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-
FT                   inositol-4,5-bisphosphate)"
FT                   /ligand_id="ChEBI:CHEBI:58456"
FT                   /evidence="ECO:0000250"
FT   BINDING         73
FT                   /ligand="a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-
FT                   inositol-4,5-bisphosphate)"
FT                   /ligand_id="ChEBI:CHEBI:58456"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         170
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8CHU3"
FT   MOD_RES         173
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O95208"
FT   MOD_RES         192
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         195
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         431
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         453
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         514
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O95208"
SQ   SEQUENCE   583 AA;  62349 MW;  2C2982B72C8FDC79 CRC64;
     MTTSSIRRQM KNIVNSYSEA EIKVREATSN DPWGPSSSLM TEIADLTYNV VRFSEIMSMV
     WKRLNDHGKN WRHVYKALTL LDYLIKTGSE RVAQQCRENI FAIQTLKDFQ YIDRDGKDQG
     INVREKSKQL VALLKDEERL KVERVQALKT KERMAQVATG VGSNQITFGR GSSQPNLSIS
     HSEQEYGKAG GSPASYHGST SPRVSSELEQ ARPQTSGEEE LQLQLALAMS REVAEQEERL
     RRGDDLRLQM ALEESRRDTV KVPKKKEVKA CCKPGSHSQQ TTLLDLMDAL PSSGPVAQKT
     EPWSTGTPAN QTNPWGGTVA PANISDPWPS FGTKPAASVD PWGVPTTASI QSVPKNSDPW
     AASQQPASDA GKTADAWGAA KPSPASGSFE LFSNFNGTVK DDFSEFDNLR TSKKPAESGA
     SVPPQDSRTT SPDLFESQSL TSASSKPSSA RKTPESFLGP NAALVNLDSL VTKPAPPAQS
     LNPFLAPGAA APAPVNPFQV NQPQPLTLNQ LRGSPVLGSS ASFGSGPGVE TVAPMPSVAP
     HSALGATGSS LTPLGPTAMN MVGSMGIPPS AAQPAGTTNP FLL
//
